Shanghai Likangrui

Shanghai Likangrui is a clinical-stage biotechnology company specializing in the development of mRNA-based vaccines and therapeutics. The company leverages its proprietary lipid nanoparticle (LNP) delivery system and mRNA synthesis technology to address unmet needs in infectious diseases and oncology. Its lead candidate, LKR-001, is an mRNA vaccine for COVID-19 that has entered clinical trials, while other programs target respiratory syncytial virus (RSV) and various cancers. Headquartered in Shanghai's Zhangjiang Hi-Tech Park, Likangrui is also advancing circular RNA (circRNA) technology to enhance the stability and duration of protein expression. The firm has secured significant backing from prominent venture capital firms like Sequoia China and Legend Capital to accelerate its pipeline development.